BOSTON (AP) — BOSTON (AP) — Verve Therapeutics Inc. (VERV) on Thursday reported a loss of $49.8 million in its second quarter.
On a per-share basis, the Boston-based company said it had a loss of 59 cents.
The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 68 cents per share.
The biotechnology firm posted revenue of $6.7 million in the period.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VERV at https://www.zacks.com/ap/VERV
